Geron Corp. Stock
€4.26
Your prediction
Financial data and news for Geron
sharewise wants to provide you with the best news and tools for Geron, so we directly link to the best financial data sources.
Financials
News
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. (NASDAQ: GERN) is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their
Is Geron Stock a Buy Following Its First New Drug Approval?
Shares of Geron (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades.
On June 6, the U.S. Food
Geron (GERN) Q1 2024 Earnings Call Transcript
Geron (GERN) Q4 2023 Earnings Call Transcript
Geron Corporation: FDA Approval Fuels Stock Price Surge
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation (NASDAQ: GERN) into the spotlight, sparking a surge in Geron’s stock price and attracting heightened attention